Matches in Nanopublications for { ?s ?p "[As compared with patients in whom the TET2 mutation was acquired first (hereafter referred to as 'TET2-first patients'), patients in whom the Janus kinase 2 (JAK2) mutation was acquired first ('JAK2-first patients') had a greater likelihood of presenting with polycythemia vera than with essential thrombocythemia, an increased risk of thrombosis, and an increased sensitivity of JAK2-mutant progenitors to ruxolitinib in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 7 of
7
with 100 items per page.
- NP519444.RA_2S6zgjysgnXrOlLs2uqcDA7NrHeKL6Hp52ww6YODk8130_assertion description "[As compared with patients in whom the TET2 mutation was acquired first (hereafter referred to as 'TET2-first patients'), patients in whom the Janus kinase 2 (JAK2) mutation was acquired first ('JAK2-first patients') had a greater likelihood of presenting with polycythemia vera than with essential thrombocythemia, an increased risk of thrombosis, and an increased sensitivity of JAK2-mutant progenitors to ruxolitinib in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP519444.RA_2S6zgjysgnXrOlLs2uqcDA7NrHeKL6Hp52ww6YODk8130_provenance.
- assertion description "[As compared with patients in whom the TET2 mutation was acquired first (hereafter referred to as 'TET2-first patients'), patients in whom the Janus kinase 2 (JAK2) mutation was acquired first ('JAK2-first patients') had a greater likelihood of presenting with polycythemia vera than with essential thrombocythemia, an increased risk of thrombosis, and an increased sensitivity of JAK2-mutant progenitors to ruxolitinib in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[As compared with patients in whom the TET2 mutation was acquired first (hereafter referred to as 'TET2-first patients'), patients in whom the Janus kinase 2 (JAK2) mutation was acquired first ('JAK2-first patients') had a greater likelihood of presenting with polycythemia vera than with essential thrombocythemia, an increased risk of thrombosis, and an increased sensitivity of JAK2-mutant progenitors to ruxolitinib in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[As compared with patients in whom the TET2 mutation was acquired first (hereafter referred to as 'TET2-first patients'), patients in whom the Janus kinase 2 (JAK2) mutation was acquired first ('JAK2-first patients') had a greater likelihood of presenting with polycythemia vera than with essential thrombocythemia, an increased risk of thrombosis, and an increased sensitivity of JAK2-mutant progenitors to ruxolitinib in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[As compared with patients in whom the TET2 mutation was acquired first (hereafter referred to as 'TET2-first patients'), patients in whom the Janus kinase 2 (JAK2) mutation was acquired first ('JAK2-first patients') had a greater likelihood of presenting with polycythemia vera than with essential thrombocythemia, an increased risk of thrombosis, and an increased sensitivity of JAK2-mutant progenitors to ruxolitinib in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP914072.RAm6R9pDyHVjTM41W2ps-Kb-i7KDcCpm6Fg4JqPgItd0s130_assertion description "[As compared with patients in whom the TET2 mutation was acquired first (hereafter referred to as 'TET2-first patients'), patients in whom the Janus kinase 2 (JAK2) mutation was acquired first ('JAK2-first patients') had a greater likelihood of presenting with polycythemia vera than with essential thrombocythemia, an increased risk of thrombosis, and an increased sensitivity of JAK2-mutant progenitors to ruxolitinib in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP914072.RAm6R9pDyHVjTM41W2ps-Kb-i7KDcCpm6Fg4JqPgItd0s130_provenance.
- NP519411.RAqFrQpUvjIUTw6vu6F9j31-_IVDXoVISQBZZSlJPRprw130_assertion description "[As compared with patients in whom the TET2 mutation was acquired first (hereafter referred to as 'TET2-first patients'), patients in whom the Janus kinase 2 (JAK2) mutation was acquired first ('JAK2-first patients') had a greater likelihood of presenting with polycythemia vera than with essential thrombocythemia, an increased risk of thrombosis, and an increased sensitivity of JAK2-mutant progenitors to ruxolitinib in vitro.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP519411.RAqFrQpUvjIUTw6vu6F9j31-_IVDXoVISQBZZSlJPRprw130_provenance.